BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

672 related articles for article (PubMed ID: 10229633)

  • 1. Novel derivatives of 2-pyridinemethylamine as selective, potent, and orally active agonists at 5-HT1A receptors.
    Vacher B; Bonnaud B; Funes P; Jubault N; Koek W; Assié MB; Cosi C; Kleven M
    J Med Chem; 1999 May; 42(9):1648-60. PubMed ID: 10229633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of a series of 6-substituted-2-pyridinylmethylamine derivatives as novel, high-affinity, selective agonists at 5-HT1A receptors.
    Vacher B; Bonnaud B; Funes P; Jubault N; Koek W; Assié MB; Cosi C
    J Med Chem; 1998 Dec; 41(25):5070-83. PubMed ID: 9836623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-HT1A receptor activation and antidepressant-like effects: F 13714 has high efficacy and marked antidepressant potential.
    Koek W; Vacher B; Cosi C; Assié MB; Patoiseau JF; Pauwels PJ; Colpaert FC
    Eur J Pharmacol; 2001 May; 420(2-3):103-12. PubMed ID: 11408031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual, hyperalgesic, and analgesic effects of the high-efficacy 5-hydroxytryptamine 1A (5-HT1A) agonist F 13640 [(3-chloro-4-fluoro-phenyl)-[4-fluoro-4-{[(5-methyl-pyridin-2-ylmethyl)-amino]-methyl}piperidin-1-yl]methanone, fumaric acid salt]: relationship with 5-HT1A receptor occupancy and kinetic parameters.
    Bardin L; Assié MB; Pélissou M; Royer-Urios I; Newman-Tancredi A; Ribet JP; Sautel F; Koek W; Colpaert FC
    J Pharmacol Exp Ther; 2005 Mar; 312(3):1034-42. PubMed ID: 15528450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-efficacy 5-HT1A agonists for antidepressant treatment: a renewed opportunity.
    Maurel JL; Autin JM; Funes P; Newman-Tancredi A; Colpaert F; Vacher B
    J Med Chem; 2007 Oct; 50(20):5024-33. PubMed ID: 17803293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. F 11440, a potent, selective, high efficacy 5-HT1A receptor agonist with marked anxiolytic and antidepressant potential.
    Koek W; Patoiseau JF; Assié MB; Cosi C; Kleven MS; Dupont-Passelaigue E; Carilla-Durand E; Palmier C; Valentin JP; John G; Pauwels PJ; Tarayre JP; Colpaert FC
    J Pharmacol Exp Ther; 1998 Oct; 287(1):266-83. PubMed ID: 9765347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New benzocycloalkylpiperazines, potent and selective 5-HT1A receptor ligands.
    el Ahmad Y; Laurent E; Maillet P; Talab A; Teste JF; Dokhan R; Tran G; Ollivier R
    J Med Chem; 1997 Mar; 40(6):952-60. PubMed ID: 9083484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and structure-activity relationships of a new model of arylpiperazines. 4. 1-[omega-(4-Arylpiperazin-1-yl)alkyl]-3-(diphenylmethylene) - 2, 5-pyrrolidinediones and -3-(9H-fluoren-9-ylidene)-2, 5-pyrrolidinediones: study of the steric requirements of the terminal amide fragment on 5-HT1A affinity/selectivity.
    López-Rodríguez ML; Morcillo MJ; Rovat TK; Fernández E; Vicente B; Sanz AM; Hernández M; Orensanz L
    J Med Chem; 1999 Jan; 42(1):36-49. PubMed ID: 9888831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 10-substituted 11-oxygenated (R)-aporphines: synthesis, pharmacology, and modeling of 5-HT1A receptor interactions.
    Hedberg MH; Jansen JM; Nordvall G; Hjorth S; Unelius L; Johansson AM
    J Med Chem; 1996 Aug; 39(18):3491-502. PubMed ID: 8784447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and pharmacological characterization of novel 6-fluorochroman derivatives as potential 5-HT1A receptor antagonists.
    Yasunaga T; Kimura T; Naito R; Kontani T; Wanibuchi F; Yamashita H; Nomura T; Tsukamoto S; Yamaguchi T; Mase T
    J Med Chem; 1998 Jul; 41(15):2765-78. PubMed ID: 9667967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2,3-Dihydro-2-oxo-1H-benzimidazole-1-carboxamides with selective affinity for the 5-HT(4) receptor: synthesis and structure-affinity and structure-activity relationships of a new series of partial agonist and antagonist derivatives.
    Tapia I; Alonso-Cires L; López-Tudanca PL; Mosquera R; Labeaga L; Innerárity A; Orjales A
    J Med Chem; 1999 Jul; 42(15):2870-80. PubMed ID: 10425096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of 3-aryl-1-[(4-phenyl-1-piperazinyl)butyl]indazole derivatives and their affinity to 5-HT1A serotonin and dopamine D1 receptors.
    Andronati S; Sava V; Makan S; Kolodeev G
    Pharmazie; 1999 Feb; 54(2):99-101. PubMed ID: 10084155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2.
    Leopoldo M; Lacivita E; Contino M; Colabufo NA; Berardi F; Perrone R
    J Med Chem; 2007 Aug; 50(17):4214-21. PubMed ID: 17649988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-HT1A-versus D2-receptor selectivity of flesinoxan and analogous N4-substituted N1-arylpiperazines.
    Kuipers W; Kruse CG; van Wijngaarden I; Standaar PJ; Tulp MT; Veldman N; Spek AL; IJzerman AP
    J Med Chem; 1997 Jan; 40(3):300-12. PubMed ID: 9022796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel pyridine derivatives as potent and selective CB2 cannabinoid receptor agonists.
    Chu GH; Saeui CT; Worm K; Weaver DG; Goodman AJ; Broadrup RL; Cassel JA; DeHaven RN; LaBuda CJ; Koblish M; Brogdon B; Smith S; Le Bourdonnec B; Dolle RE
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5931-5. PubMed ID: 19736007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1-Aryl-4-(4-succinimidobutyl)piperazines and their conformationally constrained analogues: synthesis, binding to serotonin (5-HT1A, 5-HT2A, 5-HT7), alpha1-adrenergic, and dopaminergic D2 receptors, and in vivo 5-HT1A functional characteristics.
    Bojarski AJ; Paluchowska MH; Duszyńska B; Kłodzińska A; Tatarczyńska E; Chojnacka-Wójcik E
    Bioorg Med Chem; 2005 Mar; 13(6):2293-303. PubMed ID: 15727878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2-Alkyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indoles as novel 5-HT6 receptor agonists.
    Mattsson C; Sonesson C; Sandahl A; Greiner HE; Gassen M; Plaschke J; Leibrock J; Böttcher H
    Bioorg Med Chem Lett; 2005 Oct; 15(19):4230-4. PubMed ID: 16055331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant 5-hydroxytryptamine 1A receptor D116A is a receptor activated solely by synthetic ligands with a rich pharmacology.
    Cussac D; Palmier C; Finana F; De Vries L; Tardif S; Léger C; Bernois S; Heusler P
    J Pharmacol Exp Ther; 2009 Oct; 331(1):222-33. PubMed ID: 19605522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1-aryl-4-[(5-methoxy-1,2,3, 4-tetrahydronaphthalen-1-yl)alkyl]piperazines and their analogues: influence of the stereochemistry of the tetrahydronaphthalen-1-yl nucleus on 5-HT1A receptor affinity and selectivity versus alpha1 and D2 receptors. 5.
    Perrone R; Berardi F; Colabufo NA; Leopoldo M; Tortorella V
    J Med Chem; 1999 Feb; 42(3):490-6. PubMed ID: 9986719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy of arylpiperazine derivatives at the central 5-HT3 receptors.
    Cappelli A; Anzini M; Vomero S; Canullo L; Mennuni L; Makovec F; Doucet E; Hamon M; Menziani MC; De Benedetti PG; Bruni G; Romeo MR; Giorgi G; Donati A
    J Med Chem; 1999 May; 42(9):1556-75. PubMed ID: 10229626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.